Bartlett & Co. LLC grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.3% in the 1st quarter, Holdings Channel reports. The firm owned 498,123 shares of the biopharmaceutical company’s stock after purchasing an additional 58,482 shares during the quarter. Bartlett & Co. LLC’s holdings in Bristol-Myers Squibb were worth $23,765,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of BMY. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $797,038,000. Oregon Public Employees Retirement Fund lifted its holdings in shares of Bristol-Myers Squibb by 2,326.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,230,504 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 8,850,072 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd lifted its holdings in shares of Bristol-Myers Squibb by 6,090.3% during the 4th quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,130,436 shares of the biopharmaceutical company’s stock valued at $214,700,000 after purchasing an additional 4,063,712 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Bristol-Myers Squibb by 90.9% during the 4th quarter. Prudential Financial Inc. now owns 4,967,474 shares of the biopharmaceutical company’s stock valued at $257,891,000 after purchasing an additional 2,365,961 shares during the last quarter. Finally, Ronna Sue Cohen lifted its holdings in shares of Bristol-Myers Squibb by 4,702.2% during the 1st quarter. Ronna Sue Cohen now owns 1,518,227 shares of the biopharmaceutical company’s stock valued at $1,518,000 after purchasing an additional 1,486,612 shares during the last quarter. Hedge funds and other institutional investors own 74.03% of the company’s stock.
Several analysts have recently commented on the company. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Thursday, March 28th. BMO Capital Markets increased their price objective on Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Thursday, April 4th. Bank of America decreased their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a report on Tuesday, February 19th. Finally, JPMorgan Chase & Co. assumed coverage on Bristol-Myers Squibb in a report on Friday, May 3rd. They set an “overweight” rating and a $62.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $57.64.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.01. The company had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the business posted $0.94 EPS. Analysts forecast that Bristol-Myers Squibb Co will post 4.18 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a $0.41 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a yield of 3.49%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/12/bartlett-co-llc-has-23-77-million-stake-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.